Price T Rowe Associates Inc Altimmune, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 22,668 shares of ALT stock, worth $165,703. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,668
Previous 15,238
48.76%
Holding current value
$165,703
Previous $156,000
3.21%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ALT
# of Institutions
190Shares Held
42.1MCall Options Held
1.05MPut Options Held
582K-
Black Rock Inc. New York, NY5.32MShares$38.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.91MShares$35.9 Million0.0% of portfolio
-
State Street Corp Boston, MA3.91MShares$28.6 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.22MShares$23.6 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$20.1 Million2.23% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $358M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...